SCOTTSDALE, Ariz., Nov. 26, 2019 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of Dr. Emanual Maverakis to its Board of Advisors. Dr. Maverakis is a renowned professor at the University of California Davis School of Medicine, holding appointments in the Department of Dermatology and in the Department of Medical Microbiology and Immunology.
A Harvard and University of California-educated dermatologist, Dr. Maverakis is an accomplished physician-researcher who specializes in treating patients with immune-mediated skin ulcers. He is the recipient of numerous honors including a Presidential Early Career Award for Scientists and Engineers, which is the highest honor bestowed by the United States government for outstanding scientists and engineers. In 2019, he was elected as a fellow of the California Academy of Sciences. Other awards include a National Institutes of Health Director’s New Innovator Award, a Career Award for Medical Scientists from the Burroughs Welcome Fund, and a Physician-Scientist Career Award from the Howard Hughes Medical Institute.
Dr. Maverakis participates as a Principal Investigator in a variety of investigator-initiated and company-sponsored clinical trials and his team has led national and international recruitment efforts for a variety of multicenter clinical studies. Additionally, Dr. Maverakis frequently serves on clinical trial study sections and participates in the grant review process for the National Institutes of Health. His publications have appeared in major scientific journals such as Nature Biotechnology, Nature Medicine, the Journal of Clinical Investigation, the Journal of Experimental Medicine, and the Proceedings of the National Academy of Sciences USA.
“I am excited to advise RenovaCare on the clinical development of their SkinGun™,” said Dr. Maverakis. “Wounds of all types are a major burden to the healthcare system, and we are in desperate need of new innovative technologies to help heal these patients. I see the need every day in my own clinical practice.”
“Dr. Maverakis is a gifted physician-researcher who has extensive experience in the development of effective therapies for chronic skin wounds and ulcers. He has studied non-healing wounds, and acutely understands how vital treatment is for people with major risk-factors for infections and amputation. We are excited to welcome him to our team,” stated Mr. Alan L. Rubino, CEO and President at RenovaCare.
The Maverakis Lab, established and managed by Dr. Maverakis, investigates the pathophysiology of autoimmunity, how T cells (a type of white blood cell) develop and mature, and cancer immunotherapy. His group is also interested in how foods interact with the immune system; how the immune system recognizes cancer, especially melanoma; developing novel hydrogels, especially with regards to delivering stem cells and immunotherapeutics; clinical trial design, and outcome measures. Some diseases of special interest include psoriasis, scleroderma, pyoderma gangrenous, pemphigus vulgaris, bullous pemphigoid, melanoma, and cutaneous T cell lymphoma. The Maverakis Lab group has published in a variety of journals including the Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, the Journal of Experimental Medicine and Nature Reviews Immunology.
Today’s news follows the recent appointment of Dr. Robin Robinson, founding director of BARDA, as the Vice-President of Scientific Affairs, and also the recent announcement of the USPTO awarding a new patent to RenovaCare, allowing its SkinGun™ to now spray all varieties of tissues and cells, and thus opening the door for its potential application in regenerative applications beyond skin.
Recent breakthroughs in stem cell therapies include the regeneration of human organs, tissues and bone. RenovaCare believes that the ultra-gentle spray-on application of such cells could be investigated and developed by way of commercial and academic collaborations.
Spraying Skin Stem Cells onto Burns and Wounds
To date, over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Company’s SkinGun™, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options, such as in-vitro cultured epithelial grafts that require a specialized and expensive external laboratory.
Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially weeks of hospitalization. Clinical outcomes of early experimental treatments have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery.
Patients who undergo skin grafting, today’s default treatment of care, can remain hospitalized for weeks and even months, and often enduring painful and costly surgeries and prolonged physical therapy. Some of these patients may also suffer from the psychological effects of disfigurement caused by permanent scarring and often cope with the ongoing use of pain medications and protracted joint mobility issues.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
For additional information, please call Amit Singh at: 888-398-0202 or visit: http://renovacareinc.com
To receive future press releases via email, please visit: http://renovacareinc.com/investors/register/
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/
Follow us on Twitter: https://twitter.com/RenovaCareInc
Follow us on Facebook: https://www.facebook.com/renovacarercar
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company's technologies, technical problems with the Company's research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.